These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11977108)

  • 1. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats.
    Zara GP; Bargoni A; Cavalli R; Fundarò A; Vighetto D; Gasco MR
    J Pharm Sci; 2002 May; 91(5):1324-33. PubMed ID: 11977108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
    Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
    J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.
    Looby M; Linke R; Weiss M
    Cancer Chemother Pharmacol; 1997; 39(6):554-6. PubMed ID: 9118470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
    Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
    Leukemia; 1997 Dec; 11 Suppl 5():S15-21. PubMed ID: 9436933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
    Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
    Leukemia; 1996 Apr; 10(4):707-12. PubMed ID: 8618451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and toxicity of idarubicin in the rat.
    Kuhlmann O; Hofmann S; Weiss M
    Eur J Drug Metab Pharmacokinet; 2001; 26(4):215-9. PubMed ID: 11808862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.
    Eksborg S; Björkholm M; Hast R; Fagerlund E
    Anticancer Drugs; 1997 Jan; 8(1):42-7. PubMed ID: 9147610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II--tissue distribution.
    Bargoni A; Cavalli R; Zara GP; Fundarò A; Caputo O; Gasco MR
    Pharmacol Res; 2001 May; 43(5):497-502. PubMed ID: 11394943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia.
    Fukushima T; Yamashita T; Goto N; Ueda T; Okabe KI; Kuraishi Y; Ohno R; Urabe A; Ogawa M
    Int J Hematol; 2001 Oct; 74(3):297-302. PubMed ID: 11721966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
    Tamura K
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicin.
    Toffoli G; Sorio R; Basso B; Aita P; Corona G; Rupolo M; Boiocchi M
    J Chemother; 2004 Apr; 16(2):193-200. PubMed ID: 15216956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
    Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
    Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients.
    Robert J; Rigal-Huguet F; Huet S; Pris J; Hurteloup P
    Leukemia; 1990 Mar; 4(3):227-9. PubMed ID: 2179640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN).
    Zara GP; Cavalli R; Fundarò A; Bargoni A; Caputo O; Gasco MR
    Pharmacol Res; 1999 Sep; 40(3):281-6. PubMed ID: 10479474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transmucosal transport of tobramycin incorporated in SLN after duodenal administration to rats. Part I--a pharmacokinetic study.
    Cavalli R; Zara GP; Caputo O; Bargoni A; Fundarò A; Gasco MR
    Pharmacol Res; 2000 Dec; 42(6):541-5. PubMed ID: 11058406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of idarubicin and idarubicinol on rat coronary resistance and vasoconstrictor responsiveness of isolated aorta and mesentery.
    Weiss M; Giessler C; Kang W
    Anticancer Drugs; 2006 Jan; 17(1):69-74. PubMed ID: 16317292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity.
    Dos Santos N; Waterhouse D; Masin D; Tardi PG; Karlsson G; Edwards K; Bally MB
    J Control Release; 2005 Jun; 105(1-2):89-105. PubMed ID: 15878792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of toxicokinetic and tissue distribution of triptolide-loaded solid lipid nanoparticles vs free triptolide in rats.
    Xue M; Zhao Y; Li XJ; Jiang ZZ; Zhang L; Liu SH; Li XM; Zhang LY; Yang SY
    Eur J Pharm Sci; 2012 Nov; 47(4):713-7. PubMed ID: 22677813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
    Tidefelt U; Prenkert M; Paul C
    Cancer Chemother Pharmacol; 1996; 38(5):476-80. PubMed ID: 8765443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.